

Clinical Pharmacy Program Guidelines for Inlyta

Program	Prior Authorization
Medication	Inlyta® (axitinib)
Issue Date	9/2014
Pharmacy and Therapeutics Approval Date	7/2017
Effective Date	9/2017

1. Background:

Inlyta® (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.¹ The NCCN (National Comprehensive Cancer Network) recommends use of Inlyta for treatment of follicular, Hürthle cell and papillary carcinomas.²

2. Coverage Criteria:

<p>A. <u>Advanced Renal Cell Carcinoma</u></p> <p>1. <u>Initial Authorization</u></p> <p>a. Inlyta will be approved based on <u>all</u> of the following criteria:</p> <p>(1) Diagnosis of renal cell cancer</p> <p style="text-align: center;">-AND-</p> <p>(2) <u>One</u> of the following:</p> <p>(a) Disease has relapsed</p> <p style="text-align: center;">-OR-</p> <p>(b) <u>Both</u> of the following:</p> <p style="padding-left: 40px;">i. Medically or surgically unresectable tumor</p> <p style="padding-left: 40px;">ii. Diagnosis of Stage IV disease</p> <p style="text-align: center;">Authorization will be issued for 12 months.</p>
--

2. Reauthorization

a. **Inlyta** will be approved based on the following criterion:

- (1) Patient does not show evidence of progressive disease while on Inlyta therapy

Authorization will be issued for 12 months.

B. Thyroid Carcinoma

1. Initial Authorization

a. **Inlyta** will be approved based on **all** of the following criteria:

- (1) **One** of the following diagnosis:

- (a) Follicular Carcinoma
- (b) Hürthle Cell Carcinoma
- (c) Papillary Carcinoma

-AND-

- (2) **One** of the following:

- (a) Unresectable recurrent
- (b) Persistent locoregional disease
- (c) Metastatic disease

-AND-

- (3) Disease is refractory to radioactive iodine treatment

Authorization will be issued for 12 months.

2. Reauthorization

a. **Inlyta** will be approved based on the following criterion:

- (1) Patient does not show evidence of progressive disease while on Inlyta therapy

Authorization will be issued for 12 months.

3. References:

1. Inlyta [package insert]. New York, NY: Pfizer, Inc.; August 2014.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed June 6, 2017.

Program	Prior Authorization –Inlyta (axitinib)
Change Control	
Date	Change
9/2014	New guideline
7/2016	Updated clinical criteria to align with Employer and Individual notification policy and updated policy to new template
7/2017	Annual review with no change to criteria. Updated references.